Amazon kicks off an "Alexa diabetes challenge."
Former FDA commissioner Robert Califf is in talks with Google's life sciences arm Verily for a leadership role.
The increases fit a pattern of drugmakers making single-digit percentage hikes once or twice a year, despite political pressure.
European markets closed slightly lower on Friday as investors reacted to fresh earnings and geopolitical tensions.
Jim Cramer reviews the impact of President Trump’s proposed tax cuts, and finds one juicy perk.
Jim Cramer flies through his take on caller favorite stocks, including this wings franchise.
Jim Cramer offered his advice to NextEra Energy for the company to retain its growth status in the utility sector.
Jim Cramer rattled off his take on caller favorite stocks, including this Amazon competitor.
Japan's Takeda Pharmaceutical said on Wednesday it had completed enrolment for a 20,000-subject dengue vaccine trial.
EpiPen's seller Mylan came under fire last summer for having increased the price of the auto-injector more than 500 percent.
President Donald Trump told Congress that more needs to be done to bring down "artificially high" prices for drugs, while at the same time praising a drug that turns out to cost $300,000 per year.
The hire signals Carl Icahn may be back, at a time when biotech valuations are 25 percent off their 2015 highs.
European stocks closed higher on Wednesday as the earnings season continued to be the main focus for investors.
Some of the names on the move ahead of the open.
Senator Klobuchar wants drugmaker Kaleo to explain the $4,500 price tags on its autoinjector devices for opioid overdose and food allergies.
European markets closed lower on Tuesday as investors focused on data and earnings while keeping an eye on Trump's immigration policy.
China is set to add more than 300 new and traditional drugs to its list of medicines the state will help patients pay for.
The Fast Money traders discuss whether the pharmaceutical company will be acquired.
European markets closed flat as investors cautiously awaited the inauguration of soon-to-be U.S. President Donald Trump.
Have allergies? This EpiPen rival has a list price of $4,500, but most patients won't pay a cent.